InspireMD arrives at its May 4 earnings call having shed nearly 30% in a month, yet options positioning tells a sharply different story — one of unusual bullish conviction at the lows.
The most striking signal this week is in options. Call demand has completely overwhelmed put demand, with the put/call ratio dropping to 0.0017 — the lowest reading of the past 52 weeks, and more than two standard deviations below its 20-day average of 0.0032. That level sits at the 52-week floor, not the ceiling. Traders are not hedging into this print; they are making directional bets to the upside with near-total absence of protective put buying. Whether that reflects genuine conviction or simply a very thin options market, the lean is unmistakably bullish.
The price action itself provides the backdrop for that positioning. The stock is trading at $1.15 — down 8% on the week and nearly 30% over the past month. The decline from early April highs has been grinding and persistent rather than a single-session event, suggesting sellers have been in control throughout. Closest peers offered little shelter this week: PODD dropped 7.7% and LIVN fell 5%, broadly consistent with broader pressure on medical device names.
Short interest is not the story here. At just 0.12% of the free float, positioned shorts represent almost no footprint in the stock. The week-on-week increase of roughly 35% looks alarming in percentage terms but translates to a tiny absolute move — from around 24,000 shares to 33,000. Borrow costs at 4.8% are unremarkable, and availability in the lending pool is loose. There is no short squeeze dynamic, no borrow squeeze, and no meaningful bear conviction in the lending market.
Where the data gets more interesting is in the institutional register. OrbiMed Advisors held more than 6.5% of shares as of year-end and added 1 million shares in the most recent period — a notable accumulation from a specialist healthcare fund. Aberdeen Group also added to their position in Q1 2026. Against that backdrop, the CCO Shane Gleason ran a steady programme of small sells in January and early February, totalling around $90,000 across ten transactions — routine-looking disposals that do not materially change the ownership picture.
Analyst coverage is thin and dated, with the most recent rating change from Piper Sandler cutting their target to $4.00 back in May 2025 — too stale to carry fresh weight. Two analysts who cover the name both rate it Outperform or equivalent, and the consensus target remains around $5.00. Against a stock trading at $1.15, that implies considerable upside on paper, though the gap also reflects how far shares have drifted since those targets were set.
The last earnings print, in March 2026, produced a 4.5% next-day decline followed by a modest five-day recovery. With the stock now 30% lower than a month ago and options traders piling into calls, the May 4 report is the next data point that can either validate or unwind that accumulated bullish positioning.
See the live data behind this article on ORTEX.
Open NSPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
